Brief: Champignon To Acquire Altmed Capital Corp
April 9 (Reuters) - Champignon Brands Inc SHRM.CD :
* CHAMPIGNON TO ACQUIRE ALTMED CAPITAL CORP., CONTRIBUTING
HEALTH
CANADA'S ONLY APPROVED PSYCHEDELIC MEDICINE CLINIC, SOPS FOR
CLINICAL EXPANSION, EXISTING IP & MULTIPLE TRIALS
* CHAMPIGNON BRANDS - WITH THIS ACQUISITION, CO WILL NOW
HAVE
THREE TRIALS IN PHASE I STAGE AND THREE TRIALS IN PRECLINICAL
STAGE DURING 2020
* CO WILL ALSO HAVE SEVEN IP PATENTS FOR ITS
KETAMINE/PSILOCYBIN
DELIVERY PLATFORMS AND FORMULATIONS
Source text for Eikon: ID:nGNX3F3PPx
Further company coverage: SHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Braxia Scientific
See all newsBrief: Braxia Scientific Reports Q3 2022 Financial Results
Brief: Braxia Scientific CEO Roger Mcintyre To Join Advisory Board Of At-Home Telemedicine Platform KetaMD
Brief: Braxia Scientific To Commence Canada's First Multiple-Dose Psilocybin Trial For Treatment Resistant Depression
Brief: Braxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program
Brief: Braxia Scientific Awarded Government Of Canada Funding To Complete First Of Its Kind Ketamine Clinical Trial For Bipolar Depression